Literature DB >> 25190285

Dendritic cell-targeted vaccines--hope or hype?

Wolfgang Kastenmüller1, Kathrin Kastenmüller2, Christian Kurts3, Robert A Seder4.   

Abstract

The development of an effective vaccine that elicits a strong and durable T cell response against intracellular pathogens and cancer is a challenge. One strategy to enhance the effectiveness of vaccination is by targeting dendritic cells (DCs). In this Opinion article, we discuss existing DC-targeting approaches that induce adaptive immunity. We highlight the crucial issues that need to be addressed to move the field forward and discuss whether targeting DCs could be better than current vaccine approaches.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25190285     DOI: 10.1038/nri3727

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  69 in total

1.  Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites.

Authors:  A A Horner; S K Datta; K Takabayashi; I M Belyakov; T Hayashi; N Cinman; M D Nguyen; J H Van Uden; J A Berzofsky; D D Richman; E Raz
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

2.  Class II-targeted antigen is superior to CD40-targeted antigen at stimulating humoral responses in vivo.

Authors:  D Frleta; D Demian; W F Wade
Journal:  Int Immunopharmacol       Date:  2001-02       Impact factor: 4.932

3.  Circumvention of regulatory CD4(+) T cell activity during cross-priming strongly enhances T cell-mediated immunity.

Authors:  Antje Heit; Friedemann Gebhardt; Katharina Lahl; Michael Neuenhahn; Frank Schmitz; Florian Anderl; Hermann Wagner; Tim Sparwasser; Dirk H Busch; Kathrin Kastenmüller
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 5.532

4.  Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype.

Authors:  Mireille H Lahoud; Fatma Ahmet; Susie Kitsoulis; Soo San Wan; David Vremec; Chin-Nien Lee; Belinda Phipson; Wei Shi; Gordon K Smyth; Andrew M Lew; Yu Kato; Scott N Mueller; Gayle M Davey; William R Heath; Ken Shortman; Irina Caminschi
Journal:  J Immunol       Date:  2011-06-15       Impact factor: 5.422

5.  Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells.

Authors:  Antje Heit; Tobias Maurer; Hubertus Hochrein; Stefan Bauer; Katharina M Huster; Dirk H Busch; Hermann Wagner
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

6.  Immature human dendritic cells express asialoglycoprotein receptor isoforms for efficient receptor-mediated endocytosis.

Authors:  J Valladeau; V Duvert-Frances; J J Pin; M J Kleijmeer; S Ait-Yahia; O Ravel; C Vincent; F Vega; A Helms; D Gorman; S M Zurawski; G Zurawski; J Ford; S Saeland
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

7.  DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells.

Authors:  Jurjen Tel; Daniel Benitez-Ribas; Sander Hoosemans; Alessandra Cambi; Gosse J Adema; Carl G Figdor; Paul J Tacken; I Jolanda M de Vries
Journal:  Eur J Immunol       Date:  2011-03-17       Impact factor: 5.532

8.  Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity.

Authors:  James W Huleatt; Andrea R Jacobs; Jie Tang; Priyanka Desai; Elizabeth B Kopp; Yan Huang; Langzhou Song; Valerian Nakaar; T J Powell
Journal:  Vaccine       Date:  2006-08-22       Impact factor: 3.641

9.  Vascular normalization in Rgs5-deficient tumours promotes immune destruction.

Authors:  Juliana Hamzah; Manfred Jugold; Fabian Kiessling; Paul Rigby; Mitali Manzur; Hugo H Marti; Tamer Rabie; Sylvia Kaden; Hermann-Josef Gröne; Günter J Hämmerling; Bernd Arnold; Ruth Ganss
Journal:  Nature       Date:  2008-04-16       Impact factor: 49.962

10.  Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells.

Authors:  Dapeng Li; Gabrielle Romain; Anne-Laure Flamar; Dorothée Duluc; Melissa Dullaers; Xiao-Hua Li; Sandra Zurawski; Nathalie Bosquet; Anna Karolina Palucka; Roger Le Grand; Anne O'Garra; Gerard Zurawski; Jacques Banchereau; Sangkon Oh
Journal:  J Exp Med       Date:  2012-01-02       Impact factor: 14.307

View more
  85 in total

Review 1.  Translating nucleic acid-sensing pathways into therapies.

Authors:  Tobias Junt; Winfried Barchet
Journal:  Nat Rev Immunol       Date:  2015-08-21       Impact factor: 53.106

2.  Dendritic cell targeted vaccines: Recent progresses and challenges.

Authors:  Pengfei Chen; Xinsheng Liu; Yuefeng Sun; Peng Zhou; Yonglu Wang; Yongguang Zhang
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

Review 3.  Moving to the suburbs: T-cell positioning within lymph nodes during activation and memory.

Authors:  Joanna R Groom
Journal:  Immunol Cell Biol       Date:  2015-03-10       Impact factor: 5.126

4.  Differential use of autophagy by primary dendritic cells specialized in cross-presentation.

Authors:  Justine D Mintern; Christophe Macri; Wei Jin Chin; Scott E Panozza; Elodie Segura; Natalie L Patterson; Peter Zeller; Dorothee Bourges; Sammy Bedoui; Paul J McMillan; Adi Idris; Cameron J Nowell; Andrew Brown; Kristen J Radford; Angus Pr Johnston; Jose A Villadangos
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

Review 5.  The development of dendritic cell vaccine-based immunotherapies for glioblastoma.

Authors:  David A Reardon; Duane A Mitchell
Journal:  Semin Immunopathol       Date:  2017-01-30       Impact factor: 9.623

Review 6.  Gas-filled microbubbles: Novel mucosal antigen-delivery system for induction of anti-pathogen's immune responses in the gut.

Authors:  Blaise Corthésy; Gilles Bioley
Journal:  Gut Microbes       Date:  2017-05-25

Review 7.  An RNA toolbox for cancer immunotherapy.

Authors:  Fernando Pastor; Pedro Berraondo; Iñaki Etxeberria; Josh Frederick; Ugur Sahin; Eli Gilboa; Ignacio Melero
Journal:  Nat Rev Drug Discov       Date:  2018-09-07       Impact factor: 84.694

Review 8.  Dendritic cell based vaccination strategy: an evolving paradigm.

Authors:  Anna C Filley; Mahua Dey
Journal:  J Neurooncol       Date:  2017-04-22       Impact factor: 4.130

9.  TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs.

Authors:  Liang Cheng; Qi Wang; Guangming Li; Riddhima Banga; Jianping Ma; Haisheng Yu; Fumihiko Yasui; Zheng Zhang; Giuseppe Pantaleo; Matthieu Perreau; Sandra Zurawski; Gerard Zurawski; Yves Levy; Lishan Su
Journal:  J Clin Invest       Date:  2018-08-27       Impact factor: 14.808

10.  Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques.

Authors:  Caroline Petitdemange; Sudhir Pai Kasturi; Pamela A Kozlowski; Rafiq Nabi; Clare F Quarnstrom; Pradeep Babu Jagadeesh Reddy; Cynthia A Derdeyn; Lori M Spicer; Parin Patel; Traci Legere; Yevgeniy O Kovalenkov; Celia C Labranche; François Villinger; Mark Tomai; John Vasilakos; Barton Haynes; C Yong Kang; James S Gibbs; Jonathan W Yewdell; Dan Barouch; Jens Wrammert; David Montefiori; Eric Hunter; Rama R Amara; David Masopust; Bali Pulendran
Journal:  JCI Insight       Date:  2019-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.